Floatz logo

Toripalimab

Anal Squamous Cell Carcinoma

Sun Yat-sen Universitymonoclonal_antibodyPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

27 Active assets in the Anal Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Columbia University
Phase 2BB
Carboplatin
Fudan University
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Nivolumab
National Cancer Institute (NCI)
Phase 3BB
Atezolizumab
Oncolytics Biotech
Phase 2B

View all 39 →

Same molecule, other indications

Toripalimab is also rated in:

renal cell carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
ToripalimabDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →